ArticleJournal of medical toxicology : official journal of the American College of Medical Toxicology2026
Practice Variation in the Pharmacologic Management of Severe Alcohol Withdrawal: a Survey of Medical Toxicology and Critical Care Physicians.
Article in Journal of medical toxicology : official journal of the American College of Medical Toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSevere alcohol withdrawal is associated with substantial morbidity, mortality, and resource utilization, yet evidence guiding optimal pharmacologic management remains limited. Although benzodiazepines have traditionally been recommended as first-line therapy, current professional guidelines vary. The overall aim is to determine if treatment heterogeneity or practice patterns exist for severe alcohol withdrawal.
methodsA scenario-based, self-administered survey of attending physicians who regularly treat severe alcohol withdrawal was performed. Survey invitations were distributed to members of the American College of Medical Toxicology and the University of Pittsburgh Medical Center ICU Service Center. Questions assessed initial medication choice, dosing, drug changes after inadequate response, assessment tools, strategies, physician demographics, and willingness to participate in future clinical trials.
resultsAmong 787 physicians invited, 252 responded. Respondents most commonly selected phenobarbital as initial therapy (53.0%), followed by benzodiazepines (41.4%). Phenobarbital was also the most frequently continued drug when selected initially and the most common alternative when initial therapy failed. However, practice patterns varied by specialty. Most respondents preferred symptom-triggered dosing guided by an alcohol withdrawal assessment scale, CIWA-Ar.
conclusionsThis survey demonstrates that phenobarbital and benzodiazepines are the reported preferred treatments for severe alcohol withdrawal among medical toxicologists and critical care medicine physicians, with a slight overall preference for phenobarbital. Respondents also favored symptom-triggered dosing guided by a withdrawal-specific assessment scale, such as the CIWA-Ar. Importantly, these findings underscore substantial variability in clinical practice and clinician interest in randomized trials to identify optimal treatment strategies for severe alcohol withdrawal.
Indexed as
Identifiers
42811223What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.